Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - dapagliflozinum, saxagliptinum - compresse rivestite con film - dapagliflozinum 10 mg ut dapagliflozinum propandiolum monohydricum, saxagliptinum 5 mg ut saxagliptini hydrochloridum, cellulosum microcristallinum, lactosum 40 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidum hydrochloridum, natrii hydroxidum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: e 132, lacca, pro compresso obducto corresp. natrium max. 0.91 mg. - antidiabetico - synthetika

Unia Europejska - włoski - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - asma - farmaci per le malattie respiratorie ostruttive, - fasenra è indicato come un aggiungere il trattamento di mantenimento in pazienti adulti con grave asma eosinofila non adeguatamente controllata nonostante le alte dosi di corticosteroidi per via inalatoria più lunga durata d'azione β agonisti.

Unia Europejska - włoski - EMA (European Medicines Agency)

astrazeneca ab - sodio zirconio cyclosilicate - iperkaliemia - tutti gli altri prodotti terapeutici - lokelma è indicato per il trattamento di iperkaliemia in pazienti adulti.

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - benralizumabum - soluzione iniettabile - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - schweres eosinophiles asma - biotechnologika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - compresse rivestite con film - olaparibum 100 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.236 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), pro compresso obducto. - onkologikum - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - compresse rivestite con film - olaparibum 150 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.354 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), e 172 (nigrum), pro compresso obducto. - onkologikum - synthetika

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - ticagrelorum - compresse orodispersibili - ticagrelorum 90 mg, mannitolum, cellulosum microcristallinum, crospovidonum, xylitolum, calcii hydrogenophosphas, natrii stearylis fumaras, hydroxypropylcellulosum, silica colloidalis anhydrica, pro compresso corresp. natrium 0.53 mg. - inibizione piastrinica in combinazione con acido acetilsalicilico - synthetika

Unia Europejska - włoski - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoma, polmone non a piccole cellule - agenti antineoplastici - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Unia Europejska - włoski - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - farmaco effetti collaterali e reazioni avverse - tutti gli altri prodotti terapeutici - per i pazienti adulti trattati con un diretto del fattore xa (fxa), un inibitore (apixaban o rivaroxaban) quando inversione di anticoagulazione è necessario a causa di pericolo di vita o sanguinamento incontrollato.

Szwajcaria - włoski - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - benralizumabum - lnjektionslösung - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - schweres eosinophiles asma - biotechnologika